# A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.

> **NCT02752776** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 1660 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Secukinumab

## Key facts

- **NCT ID:** NCT02752776
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-17
- **Primary completion:** 2018-03-28
- **Final completion:** 2018-03-28
- **Target enrollment:** 1660 (ACTUAL)
- **Last updated:** 2019-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02752776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02752776, "A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02752776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*